Get the Stockscreener App
71.71
2.22%
-1.63
After Hours:
71.52
-0.19
-0.26%
Halozyme Therapeutics Inc stock is traded at $71.71, with a volume of 2.04M.
It is down -2.22% in the last 24 hours and up +5.92% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$73.34
Open:
$73.34
24h Volume:
2.04M
Relative Volume:
0.95
Market Cap:
$8.43B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
23.75
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+3.60%
1M Performance:
+5.92%
6M Performance:
+19.36%
1Y Performance:
+27.10%
1-Day Range:
$71.30
$74.48
1-Week Range:
$68.85
$74.48
52-Week Range:
$47.50
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
71.71 | 8.62B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-25 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 - AOL.com
What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders - Yahoo Finance
AlphaQuest LLC Acquires 34,011 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Setup Watch: Is Halozyme Therapeutics Inc forming a breakout patternDip Buying & AI Optimized Trading Strategy Guides - baoquankhu1.vn
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Q4 EPS Forecast for Halozyme Therapeutics Lifted by Analyst - MarketBeat
Great Lakes Advisors LLC Sells 14,747 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating - Finviz
H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating - Yahoo Finance
Halozyme stock price target maintained at $58 by Goldman Sachs - Investing.com Canada
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance - Yahoo Finance
Halozyme Acquires Surf Bio for up to $400M - Contract Pharma
H.C. Wainwright reiterates Buy rating on Halozyme stock, maintains $90 price target - Investing.com Canada
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance - MarketBeat
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth and Technical Setup - Chartmill
Federated Hermes Inc. Has $106.40 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi‑Year Share Price Gains - Yahoo Finance
Halozyme Therapeutics Projects Sustained Growth Well Into 2040 - Benzinga
Risk Off: What is Halozyme Therapeutics Incs market position2025 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn
Halozyme Deepens ENHANZE Reach With Surf Bio Deal And Takeda Tie-Up - Yahoo Finance
Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s - MarketBeat
Halozyme buys a biotech startup; Cytokinetics launches heart drug - BioPharma Dive
Halozyme Therapeutics Raises 2025, 2026 Outlooks - marketscreener.com
(HALO) Halozyme Therapeutics Expects Full Year 2026 Non-GAAP EPS Range $7.75$8.25, vs. FactSet Est of $8.24 - marketscreener.com
Halozyme Therapeutics, Inc. acquired Surf Bio, Inc. for $400 million. - marketscreener.com
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance - The Malaysian Reserve
Halozyme (HALO) Projects Strong Revenue Growth for FY26 - GuruFocus
Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Year 2026 - marketscreener.com
Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Year Ended December 31, 2025 - marketscreener.com
Enhanced Guidance Boosts Halozyme's (HALO) Growth Prospects - GuruFocus
Halozyme Lifts 2025 Revenue Outlook, FY26 Guidance - Nasdaq
Halozyme raises 2025 revenue estimates, raises 2026 and multi-year financial guidance - marketscreener.com
Hussman Strategic Advisors Inc. Reduces Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
EFG Asset Management North America Corp. Has $5.83 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
How Takeda ENHANZE License Deal in IBD Will Impact Halozyme Therapeutics (HALO) Investors - Sahm
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Exploring a 11.42% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews
Biotech Recovery: Halozyme and Catalyst Stocks Surge Amid Strong Growth - Intellectia AI
Halozyme and Catalyst Report Double-Digit Revenue Growth, Strong Outlook - Intellectia AI
Value Recap: Will Halozyme Therapeutics Inc benefit from rate cutsJuly 2025 Earnings & Free Community Supported Trade Ideas - baoquankhu1.vn
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance - Insider Monkey
Can Halozyme Therapeutics Inc benefit from deglobalizationWeekly Market Report & Target Return Focused Picks - baoquankhu1.vn
How (HALO) Movements Inform Risk Allocation Models - Stock Traders Daily
14 Best Mid-Cap Growth Stocks to Buy Right Now - Insider Monkey
Reframing The Narrative For Halozyme Therapeutics (HALO) After The Latest Analyst Price Target - Yahoo Finance
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - The Malaysian Reserve
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Share Price Consolidation - Yahoo Finance
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade - Insider Monkey
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):